Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile
Provider : Pechala's Reports
Provider : GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioLine Rx Ltd announces investigator-initiated study for Novel Chronic Myeloid Leukemia Treatment

Thursday, 10 Apr 2014 07:00am EDT 

BioLine Rx Ltd:Received final regulatory approval to evaluate BioLineRx's BL-8040.BL-8040 used in treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.Developing BL-8040 in Phase 2 study for treating acute myeloid leukemia, in a Phase 1 study for stem cell mobilization, as pre-treatment for stem cell transplantation.Company has received orphan drug designation for both these indications. 

Company Quote

-9.9 -1.83%
10:24am EST